For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
Characterization of HIV reservoirs
With Dr. Réjean Thomas and Nicolas Chomont, Ph. D.
Definition of “viral reservoir” and its clinical impact
The different types of viral reservoir
Early treatment: a means of limiting the size of viral reservoirs
A new approach being studied: reducing viral reservoirs and strengthening the immune system to control the viral load naturally
Dr. Réjean Thomas speaks with Nicolas Chomont, Assistant Professor and Researcher in the Department of Microbiology, Infectious Diseases and Immunology at Université de Montréal, on the characterization of HIV reservoirs.
The viral reservoir is defined as all the cells and tissues in which HIV persists, even in people who are receiving antiretroviral therapy.
The virus persists at blood levels so low that they are not detected using conventional viral load tests. However, as soon as treatment is discontinued, the viral load becomes positive again, generally within a few weeks.
Professor Chomont’s work is aimed at characterizing and quantifying HIV reservoirs, with a view to developing therapeutic strategies to eradicate or at least control the size of reservoirs, so that patients can pause or permanently stop their treatment.
Dr. Thomas and Professor Chomont discuss the latest developments in terms of research in this field.
Réjean Thomas, MD, Dhc
CEO – Founder
Clinique médicale l’Actuel: Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation with:
Advisory Boards: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare
Nicolas Chomont, Ph. D. has a financial interest/relationship or affiliation with:
Lab research grants: Merck
Scientific Advisory Board: Theravectys
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.